drugset
drugset / Trial / NCT00030602

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00030602 ↗

Phase 2 Completed University of Maryland, Baltimore National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent prostate cancer.

Timeline

Start
2000-01
Primary completion
2001-12
Completion
2001-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PSA-3 Vaccine — Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified — —

Indications

prostate cancer